Dallas, TX -- (SBWIRE) -- 11/19/2010 -- SandlerResearch announce Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Original Source : Musculoskeletal Disorders Therapeutics Market
http://www.sandlerresearch.org/reports/36530-musculoskeletal-disorders-therapeutics-to-2016-introduction-of-.html
Buy Now : Market Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pipeline-analysis-and-mark.html
Browse complete Report at : Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
http://www.sandlerresearch.org/reports/36530-musculoskeletal-disorders-therapeutics-to-2016-introduction-of-.html
GBI Research’s report, “Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global musculoskeletal disorders market. The report analyzes the markets for musculoskeletal disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
Annualized market data for the musculoskeletal disorders therapeutics market from 2001 to 2009, with forecasts to 2016.
Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Key drivers and restraints that have created significant impact on the market.
Competitive landscape of the global musculoskeletal disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Roche/Genentech, Novartis, Amgen, Merck/Schering-Plough, Pfizer/Wyeth, Bristol-Myers Squibb and Eli Lilly, Procter and Gamble, Johnson and Johnson, Abbott Laboratories and Boehringer Ingelheim
Key M&A activities, Licensing Agreements, that have taken place between 2008 and 2009 in the musculoskeletal disorders therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to :
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 8
2 Global Musculoskeletal Disorders Therapeutics Market: Introduction 11
2.1 GBI Research Report Guidance 12
3 Global Musculoskeletal Disorders Therapeutics Market: Market Overview 13
3.1 Introduction 13
3.2 Revenue Forecasts for the Global Musculoskeletal Disorders Therapeutics Market 14
3.2.1 Revenue 14
3.2.2 Annual Cost of Treatment (ACT) 15
3.2.3 Treatment Usage Patterns 16
3.3 Generics in Musculoskeletal Disorders Therapeutics Market 21
4 Global Musculoskeletal Disorders Therapeutics Market: Geographical Landscape 22
4.1 Revenue Analysis By Geography 22
4.2 The US 24
4.2.1 Revenue 24
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Patterns 28
4.3 Top Five EU Countries 34
4.3.1 Revenue 34
4.3.2 Annual Cost of Treatment 36
4.3.3 Treatment Usage Patterns 38
4.4 Japan 44
4.4.1 Revenue 44
4.4.2 Annual Cost of Treatment 46
4.4.3 Treatment Usage Patterns 47
5 Global Musculoskeletal Disorders Therapeutics Market: Therapeutic Landscape 53
5.1 Osteoporosis Therapeutics Market 53
5.1.1 Introduction 53
5.1.2 Revenue 53
5.1.3 Annual Cost of Treatment 55
5.1.4 Treatment Usage Patterns 57
5.1.5 Drivers and Barriers for the Osteoporosis Therapeutics Market 64
5.1.6 Opportunity and Unmet Need 65
5.2 Osteoarthritis Therapeutics Market 66
5.2.1 Introduction 66
5.2.2 Revenue 66
5.2.3 Annual Cost of Treatment 68
5.2.4 Treatment Usage Patterns 69
5.2.5 Drivers and Barriers for the Osteoarthritis Therapeutics Market 76
5.2.6 Opportunity and Unmet Need 77
5.3 Rheumatoid Arthritis Therapeutics Market 78
5.3.1 Introduction 78
5.3.2 Revenue 78
5.3.3 Annual Cost of Treatment 80
5.3.4 Treatment Usage Patterns 82
5.3.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 88
5.3.6 Unmet Need for Rheumatoid Arthritis Therapeutics Market 89
5.4 Muscular Dystrophy Therapeutics Market 90
5.4.1 Introduction 90
5.4.2 Revenue 90
5.4.3 Annual Cost of Treatment 92
5.4.4 Treatment Usage Patterns 93
5.4.5 Drivers and Barriers for the Muscular Dystrophy Therapeutics Market 100
5.4.6 Unmet Need for Muscular Dystrophy Therapeutics Market 101
6 Global Musculoskeletal Disorders Therapeutics Market: Pipeline Analysis 102
6.1 Introduction 102
6.1.1 Research and Development Pipeline – Osteoarthritis 103
6.1.2 Research and Development Pipeline – Osteoporosis 109
6.1.3 Research and Development Pipeline – Rheumatoid Arthritis 118
6.1.4 Research and Development Pipeline – Muscular Dystrophy 129
6.2 Profiles of Promising Drugs in the Musculoskeletal Disorders Therapeutics Market 132
6.2.1 Catena/Sovrima (Idebenone) 132
6.2.2 IPlex(TM) (Mecasermin Rinfabate) 132
6.2.3 CG5503 (Tapentadol ER) 133
7 Global Musculoskeletal Disorders Therapeutics Market: Competitive Landscape 134
7.1 Evolving competitive landscape 134
7.1.1 Major Players 135
7.2 Market Share Analysis 136
7.3 Competitive Profiling 137
7.3.1 Novartis AG 137
7.3.2 Pfizer 138
7.3.3 Hoffmann-La Roche Ltd. 139
7.3.4 Merck & Co., Inc 141
7.3.5 Eli Lilly and Company 143
7.3.6 Abbott Laboratories 145
7.3.7 Johnson & Johnson 146
7.3.8 Amgen Inc. 147
7.3.9 Procter & Gamble Company 149
7.3.10 Bristol-Myers Squibb Company 150
8 Global Musculoskeletal Disorders Therapeutics Market: M&A Landscape 152
8.1 Overview 152
8.1.1 Pfizer Acquires Wyeth 153
8.1.2 Cephalon Acquires Arana Therapeutics 153
8.1.3 Aspen Pharmacare Acquires Sigma Pharmaceuticals 153
8.2 R&D Licensing Agreements 153
8.2.1 Deals by Phase 153
8.2.2 Deals by Geography 154
8.2.3 Deals by Value ($) 155
8.2.4 Preclinical 156
8.2.5 Phase I 157
8.2.6 Phase II 158
8.2.7 Phase III 159
8.2.8 Approved 160
8.2.9 Marketed Drugs 162
9 Global Musculoskeletal Disorders Therapeutics Market: Appendix 163
9.1 Market Definitions 163
9.2 Abbreviations 163
9.3 Research Methodology 165
9.3.1 Coverage 165
9.3.2 Secondary Research 165
9.3.3 Primary Research 166
9.3.4 Forecasts 166
9.3.5 Expert Panel Validation 169
9.4 Contact Us 169
9.5 Disclaimer 169
9.6 Sources 169
ABBREVIATIONS
Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/
Browse all : GBI Research Market
http://www.sandlerresearch.org/publishers/gbi-research/
Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx
Related Reports:
Monoclonal antibodies: 2009 update
http://www.sandlerresearch.org/Reports/7621-monoclonal-antibodies-2009-update.html
Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition
http://www.sandlerresearch.org/Reports/9248-commercial-insight-rheumatoid-arthritis-anti-tnfs-defend-first.html
Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments
http://www.sandlerresearch.org/Reports/26962-pipeline-and-commercial-insight-migraine-challenges-ahead-for-.html
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
http://www.sandlerresearch.org/Reports/34581-stakeholder-insight-rheumatoid-arthritis-rising-competition-by.html
Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
http://www.sandlerresearch.org/Reports/7856-commercial-insight-antidepressants-novel-mechanism-offers-hope.html
About Us:
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.
We also provide 24/7 online and offline support to our customers
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/